Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guadecitabine - Astex Pharmaceuticals

Drug Profile

Guadecitabine - Astex Pharmaceuticals

Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; DNMT-inhibitor-SGI-110; Guadecitabine-sodium; S-110; SGI-110

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; AstraZeneca; Big Ten Cancer Research Consortium; Fox Chase Cancer Center; Indiana University School of Medicine; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Southern California; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Furans; Purine nucleotides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Fallopian tube cancer; Gastrointestinal stromal tumours; Liver cancer; Myeloproliferative disorders; Peritoneal cancer; Phaeochromocytoma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; T-cell lymphoma; Urogenital cancer
  • Phase I/II Bladder cancer; Colorectal cancer; Renal cancer
  • Suspended Chondrosarcoma
  • No development reported Cholangiocarcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Testicular cancer
  • Discontinued Acute myeloid leukaemia; Ovarian cancer

Most Recent Events

  • 16 May 2023 Updated efficacy data from a phase I NIBIT-M4 trial in Melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 31 Mar 2023 Northwestern University completes a phase-II clinical trials in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02901899)
  • 31 Mar 2023 Northwestern University completes a phase-II clinical trials in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02901899)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top